Word

VALOTX

Status

Dead

Status Code

605

Status Date

Tuesday, November 7, 2023

Serial Number

79351089

Mark Type

4

Filing Date

Thursday, April 21, 2022

Published for Opposition

Tuesday, November 7, 2023

Abandoned Date

Tuesday, November 7, 2023

Trademark Owner History

Valo Therapeutics Oy - Owner At Publication

Classifications

40 Contract manufacturing of pharmaceuticals, cells and gene therapy reagents, including custom manufacturing services of pharmaceuticals, cells and gene therapy reagents; custom manufacturing services for others in the field of pharmaceuticals, biopharmaceuticals, cellular immunotherapies, health care products and medical products; manufacture of pharmaceuticals and biopharmaceuticals to order and/or specification of others; custom manufacturing of biological tissue, blood, and cells (including stem and progenitor cells, adult cells and immune cells); treatment of materials, namely, pharmaceutical and chemical products and their components used in the manufacture of pharmaceuticals and biopharmaceuticals and cellular immunotherapies

5 Biopharmaceutical and pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; veterinary preparations; biological preparations for veterinary purposes for the treatment of tumors, cancers and infectious diseases; cultures of microorganisms for medical and veterinary use; biological preparations for medical purposes for the treatment of tumors, cancers and infectious diseases; drugs for medical purposes for the treatment of tumors, cancers and infectious diseases; diagnostic preparations for medical purposes; enzymes for medical purposes; biochemical medicines for the treatment of tumors, cancers and infectious diseases; vaccines; bioengineering pharmaceutical solutions for use in expanding cells for therapeutic use to patients with blood cancers and other diseases; biopharmaceuticals for the treatment of tumors, cancers and infectious diseases; cells for medical and clinical use, including, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; diagnostic preparations for medical purposes; Pharmaceutical preparations and vaccines for use in gene therapy and cell therapy; biological preparations for use in medical and clinical gene therapy and cell therapy; pharmaceutical preparations in the nature of cell solutions to enable cell expansion for therapeutic purposes; reagents for medical use for ex vivo cell processing in particular media suitable for the expansion of cells; Stem cells for medical or veterinary use; cells for medical purposes

1 Chemical and biological reagents for scientific and research use; antioxidants for use in the manufacture of pharmaceuticals; Animal albumen as a raw material for industrial use; collagen for industrial purposes; antioxidants for use in manufacture; biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; protein for use in manufacture; preparations of microorganisms, other than for medical and veterinary use; biological preparations for use in industry and science, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes

44 Medical services, including regenerative treatment services; medical diagnostic testing, monitoring and reporting services; medical evaluation of immuno-oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; providing health and medical information about medical disorders and their diagnosis, prevention and treatment; cell and gene therapy medical treatment services

10 Medical instruments and apparatus for the administration of gene and cell therapy, immunotherapy and immunomodulation and prophylaxis products; surgical and medical apparatus and instruments for gene and cell therapy, immunotherapy and immunomodulation and prophylaxis; veterinary apparatus and instruments, namely, for use in the treatment of tumors, cancers and infectious diseases; radiological apparatus for medical purposes; diagnostic apparatus for medical purposes, namely for use in the treatment of tumors, cancers and infectious diseases; apparatus for use in medical analysis, namely, for use in the treatment of tumors, cancers and infectious diseases; medical apparatus and instruments for use in the treatment of tumors, cancers and infectious diseases; surgical apparatus and instruments; breast pumps; apparatus, devices and articles for nursing infants, namely, nursing bottles; physiotherapy apparatus, namely, foam positioning pads and rollers for physical therapy use; galvanic therapeutic appliances for medical use; blood testing apparatus; medical devices for ex vivo cell processing

42 Analysis of biological samples; biopharmaceutical and pharmaceutical development and research and evaluation services in the field of cell based therapeutics and gene therapy for the treatment of disease, injuries and disorders; biotechnology laboratory services; medical and scientific laboratory services; scientific and medical research consultation services and scientific and medical research and development services, including in the field of haematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; clinical research services in the field of in the field of haematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; medical and scientific research, namely, conducting clinical trials for others; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceutical preparations; research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations and substances for use in clinical trials; cloud computing; chemical analysis; industrial design; conducting technical project studies; research and development of new products for others; material testing; biological research; scientific laboratory services; scientific research; bacteriological research

Trademark Events

Sep 29, 2022

Sn Assigned For Sect 66a Appl From Ib

Sep 30, 2022

New Application Office Supplied Data Entered

Oct 4, 2022

Application Filing Receipt Mailed

Oct 23, 2022

New Representative At Ib Received

Feb 9, 2023

Assigned To Examiner

Feb 10, 2023

Non-Final Action Written

Feb 11, 2023

Non-Final Action (Ib Refusal) Prepared For Review

Apr 3, 2023

Refusal Processed By Mpu

Apr 3, 2023

Non-Final Action Mailed - Refusal Sent To Ib

Apr 25, 2023

Refusal Processed By Ib

Oct 1, 2023

Teas Response To Office Action Received

Oct 1, 2023

Correspondence Received In Law Office

Oct 2, 2023

Teas/Email Correspondence Entered

Oct 4, 2023

Approved For Pub - Principal Register

Oct 18, 2023

Notification Of Possible Opposition Sent To Ib

Nov 6, 2023

Notification Processed By Ib

Nov 7, 2023

Abandonment - After Publication

Oct 18, 2023

Notification Of Notice Of Publication E-Mailed

Oct 18, 2023

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Nov 2, 2023

Teas Express Abandonment Received

Nov 7, 2023

Published For Opposition

Nov 7, 2023

Official Gazette Publication Confirmation E-Mailed

Nov 7, 2023

Abandonment Notice E-Mailed - After Publication

Aug 30, 2024

New Representative At Ib Received

Nov 7, 2023

Abandonment - After Publication